Alto Neuroscience, Inc. ANRO

ANRO Company Overview

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision psychiatry treatments for neuropsychiatric disorders. The company applies biomarker-driven patient stratification, including electroencephalography (EEG), digital phenotyping, neurocognitive assessments, and other data-based approaches, to identify patient populations more likely to respond to targeted therapies. Alto primarily operates within the biotechnology and central nervous system (CNS) therapeutics industries, with a focus on conditions such as major depressive disorder (MDD), treatment-resistant depression, bipolar depression, schizophrenia-related conditions, and other psychiatric disorders with significant unmet medical need.

The company’s primary value proposition centers on combining neuroscience drug development with precision medicine methodologies intended to improve clinical trial outcomes and therapeutic response rates. Alto’s pipeline includes internally developed and in-licensed therapeutic candidates targeting specific neurobiological mechanisms. The company evolved from a data-centric neuropsychiatric research platform into a publicly traded clinical-stage biotechnology company, with its development strategy shaped around biomarker-enriched clinical trials and personalized psychiatry approaches.